Saadet AKARSU, Mustafa AYDIN, Erdal YILMAZ, Abdullah KURT, HATİCE GAMZE POYRAZOĞLU, Çıtak A. Neşe KURT

C-reaktif proteine göre hastalıklar

Amaç: C-reaktif protein (CRP) hastalıkların hızlı tanı ve prognozunu belirlemede kullanılmaktadır. Kliniğimizde tanısı kesin olarak konulmuş hastalarımızdaki CRP değerlerini tespit etmek istedik. Yöntem: Çalışma prospektif olarak 12 aylık sürede ve toplam 534 hastada yapıldı. Bulgular: Infeksiyöz nedenli 261 (% 48.9) ve infeksiyöz olmayan nedenli 273 (% 51.1) vaka vardı. Infeksiyöz nedenlilerde CRP değeri 29.1 (bakteriyel 39.3, viral 6.4) mg/L ve infeksiyöz olmayan nedenlilerde 3.7 mg/L olarak saptandı. Infeksiyöz nedenliler ile infeksiyöz olmayan nedenliler arasında istatistiksel fark vardı (p

Anahtar Kelimeler:

İleriye dönük çalışma, C-reaktif protein, Çocuk, Enfeksiyon, Tanı teknik ve işlemleri

Diseases according to C-reactive protein

Aim: C-reactive protein (CRP) is used for rapid diagnosis and prognosis of the diseases. We wanted to determine the CRP values of patients in our clinic whose illnesses were clearly diagnosed. Methods: The study was designed as prospectively and performed on 534 patients within a period of 12 months. Results: There were 261 (48.9%) and 273 (51.1%) patients with infectious and non-infectious origin, respectively. It was determined that CRP values were 29.1 (bacterial 39.3, viral 6.4) mg/L in those with infectious origin and 3.7 mg/L in non-infectious origin. There was statistically significant difference between infectious and non-infectious disease groups (p<0.05). Of those with infectious origin there was statistically significant difference between bacterial and viral causes (p<0.05). Conclusion: CRP can be used for determination of the diagnosis, prognosis of disease and response to the treatment with serial measurements.

Keywords:

Prospective Studies, C-Reactive Protein, Child, Infection, Diagnostic Techniques and Procedures,

___

1.Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004; 19: 48487-90.
2.Szalai AJ. The biological functions of C-reactive protein. Vas-cul Pharmacol 2002; 39: 105-7.
3.Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med 1999; 17: 1019-25.
4.Mortensen RF, Zhong W. Regulation of phagocytic leukocyte activities by C.-reactive protein. J Leukoc Biol 2000; 67: 495-500.
5.de Maat MP, Trion A. C-reactive protein as a risk factor versus risk marker. Curr O pin Lipidol 2004; 15: 651-7.
6.Zimmerman MA, Selzman CH, Cothren C, et al. Diagnostic implications of C-reactive protein. Arch Surg 2003; 138: 220-4.
7.Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002; 4: 250-5.
8.Rosalki SB. C-reactive protein. Int J Clin Pract 2001; 55: 269-70.
9.Dupuy AM, Terrier N, SenecaJ L, et al, Is C-reactive protein a marker of inflammation? Nephrologie 20Ö3; 24: 337-41.
10.Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J.Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206-17.
11.Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44:6-11.
12.Hansen JG, Dahler-Eriksen BS. C-reactive protein and infections in general practice. Ugeskr Laeger 2000; 162: 2457-60.
13.Yeh ET. CRP as a mediator of disease. Circulation 2004; 109: 11-4.
14.Mary R, Veinberg F, Couderc R. Acute meningitidis, acute phase proteins and procalcitonin. Ann Biol Clin (Paris) 2003; 61:127-37.
15.Tibbie JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001; 7: 460-5.
16.Rollino C, Boero R, Ferro M, et al. Acute pyelonephritis: analysis of 52 cases. Ren Fail 2002; 24: 601-8.
17.Nascimento MM, Pecoits-Filho R, Qureshi AR, et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant 2004; 19: 2803-9.
18.Hengst JM. The role of C-reactive protein in the evaluation and management of infants with suspected sepsis. Adv Neonatal Care 2003; 3: 3-13.
19.Kawczynski P, Piotrowski A. Prokalcitonin and C-reactive protein as a markers of neonatal sepsis. Ginekol Pol 2004; 75: 439-44.
20.Korppi M. Community-acquired pneumonia in children: issues in optimizing antibacterial treatment. Paediatr Drugs 2003; 5: 821-32.
21.Ito K, Yoshiyama T, Wada M, Ogata H. C-reactive protein in patients with bacteriological positive lung tuberculosis. Kekka-ku 2004; 79: 309-11.
22.Stearman M, Southgate HJ. The use of cytokine and C-reactive protein measurements in cerebrospinal fluid during acute infective meningitis. Ann Clin Biochem 1994; 31: 255-61.
23.Yılmaz A, Arıbaş ET. Menenjitlerin tanı ve izleminde serum C-reaktif protein. Genel Tıp Dergisi 2001; 11: 99-103.
24.Hallan S, Asberg A. The accuracy of C-reactive protein in diagnosing acute appendicitis-a meta-analysis. Scand J Clin Lab Invest 1997; 57: 373-80.
25.Werner J, Hartwig W, Uhl W, Muller C, Buchler MW.Useful markers for predicting severity and monitoring progression of acute pancreatitis. Pancreatology 2003; 3: 115-27.
26.Gandini D. Acute septic arthritis of the hip in children in northern Australia. ANZ J Surg 2003; 73: 136-9.
27.Tunca M, Akar S, Soyturk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial. Clin Exp Rheumatol 2004; 22: 37-40.
28.Hsu CT, Lin YT, Yang YH, Chiang BL. Factors affecting clinical and therapeutic outcomes of patients with juvenile rheumatoid arthritis. Scand J Rheumatol 2004; 33:312-7.
29.Sudhoff T, Giagounidis A, Karthaus M. Serum and plasma parameters in clinical evaluation of neutropenic fever. Antibiot Chemother 2000; 50:10-9.
30.Buyukozturk S, Gelincik AA, Gene S, et al. Acute phase re-actants in allergic airway disease. Tohoku J Exp Med 2004; 204: 209-13.
31.Sawiniec J, Gnyp L, Lewandowska-Stanek H. C-reactive protein as a useful prognostic marker in acute poisoning. Przegl Lek 2004; 61: 356-8.